drugset / Trial / NCT01659177

A Study of LY2140023 in Healthy Participants

NCT01659177

Phase 1 Withdrawn Denovo Biopharma LLC
RandomizedCrossoverOpen-labelBasic science

Summary

The study will evaluate the effect of food on absorption of LY2140023 in blood. This study involves a single dose of 80 mg LY2140023 taken as a tablet by mouth on 2 occasions, once on an empty stomach and once after eating breakfast. There is a minimum 3 day washout between doses. This study will last approximately 16 days not including screening. Screening is required within 30 days prior to the start of the study.

Timeline

Start
2012-08
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject LY2140023 Unknown 80 mg Oral

Indications

No indication recorded.